Nobuo Tsukamoto

Dr. Nobuo Tsukamoto

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2025 in Neoplasia
Verified
Journal Article
Open access
HKHiroki Kinoshita
Hiroki Kinoshita
KTKazumasa Takenouchi
Kazumasa Takenouchi
NTNobuo Tsukamoto
Nobuo Tsukamoto
KOKazunobu Ohnuki
Kazunobu Ohnuki
TSToshihiro Suzuki
Toshihiro Suzuki
TNTetsuya Nakatsura
Tetsuya Nakatsura
Targeting cancer antigens expressed in cancer cells is necessary to develop cancer-specific immunotherapy. We have performed immunohistochemical analysis of various solid cancer specimens, adding ROBO1, AFP, TGFBI, EphB4, CLDN1, and LAT1 to the previously studied glypican-3 (GPC3), HSP105α, FOXM1, and SPARC, and found that these 10 common cancer antigens are sufficient to cover most solid cancers. These antigens were frequently expressed in various solid cancers but shown to be rarely ex-pressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. In this study, we predicted 72 and 73 peptides that bind to HLA-A24 and -A2 in silico from the full-length amino acid sequences of these 10 common cancer antigens and immunized each HLA transgenic mouse with a cocktail of synthesized peptides together with the poly I:CLC three times weekly to analyze the antigen-specific immune response. As a result, 68 peptide sequences (30 and 38, respectively) were identified that had higher cytotoxic T lymphocyte (CTL) induction ability than GPC3 298-306 and GPC3 144-152 used in the clinical trials. Furthermore, experiments with cocktail peptide vaccines using mouse models expressing subcutaneous tumors of each antigen showed promising results in terms of safety and efficacy. These peptides identified in this study, derived from 10 common cancer antigens covering all solid cancers, are expected to be clinically applicable as cocktail peptide vaccines.

Verified
Journal Article
Open access
PDF file
TNTetsuya Nakatsura
Tetsuya Nakatsura
KTKazumasa Takenouchi
Kazumasa Takenouchi
Jun KataokaJun Kataoka
Jun Kataoka
YIYusuke Ito
Yusuke Ito
SKSae Kikuchi
Sae Kikuchi
NTNobuo Tsukamoto
Nobuo Tsukamoto
Although CD19 CAR-T has been highly effective against B-cell blood cancers, there are few reports of successful treatments for solid cancers, probably because there are few protein antigens specifically expressed on the surface of the cancer cell membrane. The key to developing a groundbreaking CAR-T cell therapy effective against solid cancers is to “overcome the heterogeneity of cancer antigens”. For this purpose, it is necessary to target multiple cancer antigens simultaneously. In this study, we performed immunohistochemical analysis of various solid cancer specimens using antibodies against ROBO1, EphB4, CLDN1, and LAT1 in addition to GPC3, which we have previously studied. These antigens were frequently expressed in various solid cancers but shown to be rarely expressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. Although ROBO1 and GPC3 are often expressed in cytoplasm, there are also cases in which they are expressed on the cell membrane depending on the type of cancer. On the other hand, it has been revealed that three antigens—EphB4, CLDN1, and LAT1—are frequently expressed only on the cell membrane of cancer cells in various solid cancers, suggesting that they may be ideal targets for CAR-T cell therapy.

29 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TNTetsuya Nakatsura
Tetsuya Nakatsura
KTKazumasa Takenouchi
Kazumasa Takenouchi
Jun KataokaJun Kataoka
Jun Kataoka
YIYusuke Ito
Yusuke Ito
SKSae Kikuchi
Sae Kikuchi
NTNobuo Tsukamoto
Nobuo Tsukamoto
Although CD19 CAR-T has been highly effective against B-cell blood cancers, there are few reports of successful treatments for solid cancers, probably because there are few protein antigens specifically expressed on the surface of the cancer cell membrane. The key to developing a groundbreaking CAR-T cell therapy effective against solid cancers is to "overcome the heterogeneity of cancer antigens." For this purpose, it is necessary to target multiple cancer antigens simultaneously. In this study, we performed immunohistochemical analysis of various solid cancer specimens using antibodies against ROBO1, EphB4, CLDN1, and LAT1 in addition to GPC3, which we have previously studied. These antigens were frequently expressed in various solid cancers but shown to be rarely expressed, with some exceptions, in non-cancerous normal organs adjacent to the cancer. In addition, it was revealed that the cell membrane antigens EphB4, CLDN1, and LAT1 are frequently expressed in various solid cancers. CAR-T cell therapy targeting these antigens may be a savior for many solid cancer patients. We will develop cancer immunotherapies that target these multiple common cancer membrane protein antigens.

31 March 2023
Verified
Other
Open access
NTNobuo Tsukamoto
Nobuo Tsukamoto
SOStarlyn Okada
Starlyn Okada
YOYoko Onami
Yoko Onami
YSYusuke Sasaki
Yusuke Sasaki
KUKazuo Umezawa
Kazuo Umezawa
YKYutaka Kawakami
Yutaka Kawakami

26 June 2026 in Cancer Letters
Verified
Journal Article
Open access
TTTsuyoshi Terada
Tsuyoshi Terada
TSToshihiro Suzuki
Toshihiro Suzuki
KOKazunobu Ohnuki
Kazunobu Ohnuki
TYToshiaki Yoshikawa
Toshiaki Yoshikawa
MSManami Shimomura
Manami Shimomura
TNTetsuya Nakatsura
Tetsuya Nakatsura
Glypican-3 (GPC3) is highly expressed in most hepatocellular carcinomas (HCCs) and hepatoblastoma, shows minimal expression in non-tumor adult tissues, and is also detected in several other malignancies, making it an ideal target for anticancer immunotherapy. We previously demonstrated in clinical trials that GPC3 peptide vaccination can induce durable antitumor immunity in patients with HCC and pediatric hepatoblastoma and established human leukocyte antigen (HLA)-A*02:01-restricted GPC3-specific cytotoxic T lymphocyte (CTL) clones. In this study, we isolated high-avidity T-cell receptors (TCRs) from CTL clones established from a pediatric hepatoblastoma patient who achieved long-term recurrence-free survival for more than 10 years after surgical resection of pulmonary metastases followed by GPC3 peptide vaccination. Using a retroviral vector incorporating endogenous TCR suppression, these TCR genes were introduced into primary human T cells to generate GPC3-specific TCR-engineered T cells (TCR-T cells). These TCR-T cells exhibited GPC3-specific recognition and significant cytotoxicity against GPC3-positive tumor cells in vitro, while showing minimal activity against GPC3-negative targets. Moreover, GPC3-specific TCR-T cells migrated to tumor sites, resulting in the prevention of tumor engraftment as well as tumor growth suppression and stabilization in xenograft models. GPC3-targeted TCR-T cells derived from CTLs induced by GPC3 peptide vaccination demonstrated potent antitumor activity against HLA-A*02-positive and GPC3-positive cancers. These findings provide an important rationale for Phase I clinical trials of GPC3-targeted TCR-T cells as a promising therapeutic strategy for GPC3-expressing solid tumors, including HCC and refractory hepatoblastoma.

31 March 2023
Verified
Other
Open access
NTNobuo Tsukamoto
Nobuo Tsukamoto
SOStarlyn Okada
Starlyn Okada
YOYoko Onami
Yoko Onami
YSYusuke Sasaki
Yusuke Sasaki
KUKazuo Umezawa
Kazuo Umezawa
YKYutaka Kawakami
Yutaka Kawakami